Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.7.0.1
Segment Reporting (Tables)
3 Months Ended
Feb. 28, 2017
Segment Reporting [Abstract]  
Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax benefit (expense) and other comprehensive income for the three months ended February 28, 2017 and February 29, 2016:

 

     For the three
months ended
February 28,
2017
     For the three
months ended
February 29,
2016
 

Net revenue

     

Umbilical cord blood and cord tissue stem cell service

   $ 5,611,824      $ 5,020,459  

Prepacyte®-CB

     164,800        131,739  
  

 

 

    

 

 

 

Total net revenue

   $ 5,776,624      $ 5,152,198  
  

 

 

    

 

 

 

 

Cost of sales

     

Umbilical cord blood and cord tissue stem cell service

   $ 1,392,795      $ 1,245,023  

Prepacyte®-CB

     123,302        103,268  
  

 

 

    

 

 

 

Total cost of sales

   $ 1,516,097      $ 1,348,291  
  

 

 

    

 

 

 

Depreciation and amortization

     

Umbilical cord blood and cord tissue stem cell service

   $ 22,566      $ 28,678  

Prepacyte®-CB

     9,064        12,870  
  

 

 

    

 

 

 

Total depreciation and amortization

   $ 31,630      $ 41,548  
  

 

 

    

 

 

 

Operating income

     

Umbilical cord blood and cord tissue stem cell service

   $ 1,083,692      $ 127,951  

Prepacyte®-CB

     32,434        28,471  
  

 

 

    

 

 

 

Total operating income

   $ 1,116,126      $ 156,422  
  

 

 

    

 

 

 

Interest expense

     

Umbilical cord blood and cord tissue stem cell service

   $ 297,044      $ 246,943  

Prepacyte®-CB

     —          14,391  
  

 

 

    

 

 

 

Total interest expense

   $ 297,044      $ 261,334  
  

 

 

    

 

 

 

Income tax benefit (expense)

     

Umbilical cord blood and cord tissue stem cell service

   $ (305,717    $ —    

Prepacyte®-CB

   $ —        $ —    
  

 

 

    

 

 

 

Total income tax benefit (expense)

   $ (305,717    $ —    
  

 

 

    

 

 

 

Other comprehensive income (loss)

     

Umbilical cord blood and cord tissue stem cell service

   $ (7,061    $ (93,727

Prepacyte®-CB

     —          —    
  

 

 

    

 

 

 

Total other comprehensive income (loss)

   $ (7,061    $ (93,727
     As of
February 28, 2017
     As of
November 30, 2016
 

Assets

     

Umbilical cord blood and cord tissue stem cell service

   $ 19,186,558      $ 18,960,261  

Prepacyte®-CB

     566,797        578,207  
  

 

 

    

 

 

 

Total assets

   $ 19,753,355      $ 19,538,468